Nektar CEO sells 418 shares at $71.98 to cover taxes

NEKTAR THERAPEUTICS (NKTR) reported that President & CEO and director Howard W. Robin sold 418 shares of common stock on 2026-08-18 at a weighted average price of $71.98 per share, in trades executed between $71.78 and $72.49.

Rhea-AI Filing Summary

NEKTAR THERAPEUTICS (NKTR) reported that President & CEO and director Howard W. Robin sold 418 shares of common stock on 2026-08-18 at a weighted average price of $71.98 per share, in trades executed between $71.78 and $72.49. According to the company’s disclosure, these shares were sold to cover required tax withholding obligations arising from the vesting of Robin’s RSUs and did not represent a discretionary trade. After this sale, Robin held 54,627 shares directly, and an additional 28 shares were reported as indirectly owned by his spouse.

Insider Trade Summary

Net Seller: 418 shares

Net Sell 2 txns

Insider ROBIN HOWARD W

Role President & CEO

Sold 418 shs ($30K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	418	$71.98	$30K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 54,627 shares (Direct); Common Stock — 28 shares (Indirect, by spouse)

Footnotes (2)

1. F1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
2. F2. This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

Key Figures

Shares sold: 418 shares of Common Stock Weighted average sale price: $71.98 per share Sale price range: $71.78 to $72.49 per share +3 more

6 metrics

Shares sold 418 shares of Common Stock Sale on 2026-08-18 to cover tax withholding obligations

Weighted average sale price $71.98 per share Weighted average price for the 418-share sale

Sale price range $71.78 to $72.49 per share Range of prices for multiple trades on 2026-08-18

Direct holdings after transaction 54,627 shares Common stock directly owned by Howard W. Robin after the sale

Indirect holdings after transaction 28 shares Common stock indirectly owned by Howard W. Robin, by spouse

Net shares sold 418 shares Net sell shares reported in transaction summary

Key Terms

Restricted Stock Units, weighted average sale price, indirect, tax withholding obligations

4 terms

Restricted Stock Units financial

"in connection with the vesting of the RSUs held by the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

indirect financial

"transaction_type":"holding" ... "ownership_type":"indirect""

tax withholding obligations financial

"sold by the reporting person to cover required tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NKTR’s CEO report on this Form 4?

Howard W. Robin, President & CEO of NKTR, reported selling 418 shares of common stock on 2026-08-18. The sale was made to cover tax withholding obligations related to vesting RSUs and was described as not being a discretionary trade.

At what price were the NEKTAR THERAPEUTICS (NKTR) shares sold by the CEO?

The CEO’s 418-share sale had a weighted average price of $71.98 per share, with individual trades executed at prices ranging from $71.78 to $72.49, as disclosed in the footnotes.

Was the NKTR CEO’s reported stock sale a discretionary trade?

No. The filing states the 418 shares were sold to cover required tax withholding obligations in connection with vesting RSUs and "does not represent a discretionary trade" by the reporting person.

How many NEKTAR THERAPEUTICS (NKTR) shares does the CEO hold after this transaction?

Following the reported sale, Howard W. Robin directly owned 54,627 shares of NKTR common stock. The filing also reports 28 shares as indirectly owned, held by spouse.

Does the Form 4 mention any indirect ownership for the NKTR CEO?

Yes. In addition to his direct holdings, the filing lists 28 shares of NKTR common stock as indirectly owned by Howard W. Robin, with the nature of ownership described as “by spouse.”

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2026 - 07:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBIN HOWARD W

(Last) (First) (Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		S		418(1)	D	$71.98(2)	54,627	D
Common Stock								28	I	by spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.

	Elizabeth Zhang, Attorney-in-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)